Alembic is lined up to copy 3 of the blockbuster drugs on this tracker, which earned $19.2B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Alembic's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Entresto | Novartis | Generic | 2025 | Approved May 2024 | $7.7B |
| Farxiga | AstraZeneca | Generic | 2026 | Approved Apr 2026 | $8.4B |
| Jakafi | Incyte | Generic | 2028 | In litigation | $3.1B |
Company facts: Stock Analysis. Each drug page lists sources for these entries. Brand sales show the size of the market, not Alembic's share of it.